• Mifepristone (RU486): Evidence-Based Utility in Oncology & R

  2026-07-06

  Mifepristone (RU486) is a high-purity, cell-permeable progesterone receptor antagonist validated for inhibiting reproductive and cancer-related pathways. It demonstrates potent anti-proliferative effects in multiple tumor models, with established protocol parameters and practical limitations. This article details mechanistic, application, and workflow evidence for scientific research.

• Strategic Use of 5-(N,N-dimethyl)-Amiloride in Endothelial I

  2026-07-06

  This article provides translational researchers with a mechanistic roadmap and strategic guidance for leveraging 5-(N,N-dimethyl)-Amiloride hydrochloride in the study of endothelial injury, with a focus on sepsis, cardiac dysfunction, and biomarker-driven model systems. Integrating recent advances in endothelial biomarkers—particularly moesin—and providing actionable protocol parameters, this piece advances the discussion beyond typical product descriptions, emphasizing experimental rigor, clinical relevance, and innovative research applications.

• Bestatin Hydrochloride in Angiogenesis and Tumor Research

  2026-07-05

  Bestatin hydrochloride (Ubenimex) stands out as a dual inhibitor of aminopeptidase N and B, empowering researchers to dissect tumor growth, invasion, and neuropeptide signaling. Advanced evidence and real-world protocols highlight its reliability for angiogenesis inhibition and mechanistic cancer research, with troubleshooting insights ensuring reproducible results.

• ECL Chemiluminescent Substrate Detection Kit for Low-Abundan

  2026-07-04

  The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) enables reproducible, ultrasensitive immunoblotting for low-abundance protein targets. Its extended signal duration and low background make it ideal for advanced neuroscience workflows, as illustrated by recent mitochondrial-neuronal transfer studies.

• LKB1 Regulates Telomerase via Histone Lactylation in Lung Ca

  2026-07-03

  This study elucidates how LKB1 suppresses telomerase activity and induces cellular senescence in lung adenocarcinoma through inhibition of histone H4 lactylation and Sp1-mediated TERT transcription. The findings provide a mechanistic basis for targeting telomerase regulation in cancer therapy and highlight the interplay between metabolic changes and epigenetic control.

• Naringenin Modulates ER Stress to Counter Insulin Resistance

  2026-07-03

  This study demonstrates that naringenin alleviates HCV-induced insulin resistance by attenuating endoplasmic reticulum (ER) stress, particularly the IRE1α/XBP1 pathway, in hepatocytes and mouse liver. The findings highlight a mechanistic link between viral infection, ER stress, and metabolic dysfunction, offering new avenues for therapeutic intervention.

• HOXC8 Suppresses Pyroptosis via Caspase-1 Repression in NSCL

  2026-07-02

  This study reveals that the transcription factor HOXC8 inhibits pyroptotic cell death in non-small cell lung carcinoma (NSCLC) by suppressing caspase-1 expression through recruitment of HDAC1/2 to the CASP1 promoter. These findings clarify a specific epigenetic mechanism by which HOXC8 promotes NSCLC cell survival, offering new entry points for targeted research on caspase signaling pathways and inflammation-linked tumorigenesis.

• ECL Chemiluminescent Substrate Detection Kit: HRP Workflow M

  2026-07-02

  Unlock hypersensitive HRP chemiluminescence for reliable immunoblotting detection of low-abundance proteins. This guide translates breakthrough research into practical workflows, troubleshooting, and optimized protocols with the ECL Chemiluminescent Substrate Detection Kit (Hypersensitive).

• Mifepristone (RU486): From Receptor Antagonism to Ferroptosi

  2026-07-01

  Explore the advanced molecular mechanisms and translational assay guidance for Mifepristone (RU486), a potent progesterone receptor antagonist. This article uniquely connects ferroptosis, cell cycle regulation, and reproductive signaling, providing practical insight for oncology and reproductive biology researchers.

• Epoxomicin in Viral Immunity: Proteasome Inhibition Beyond P

  2026-07-01

  Explore how Epoxomicin, a potent proteasome inhibitor, enables advanced research at the intersection of ubiquitin-proteasome pathway dynamics and viral immune evasion. This article unveils new applications in inflammation and necroptosis modeling, distinguishing itself from prior protocol- and workflow-focused guides.

• EphA2 Synthetic Lethality in MYC-Driven Triple-Negative Brea

  2026-06-30

  This study establishes a chemogenetic screening approach that identifies EphA2 inhibition as a synthetic lethal vulnerability in MYC-driven triple-negative breast cancer (TNBC). The findings highlight a promising, MYC-selective therapeutic strategy that operates independently of p53 status and is validated both in vitro and in TNBC xenograft models.

• Tunicamycin (SKU B7417): Precision N-Glycosylation Inhibitio

  2026-06-30

  This article provides scenario-driven guidance for researchers leveraging Tunicamycin (SKU B7417) as an N-glycosylation inhibitor in cell viability, proliferation, and inflammation assays. It addresses experimental design, protocol optimization, and data interpretation, highlighting the product's reproducibility and validated performance. Readers will find practical, literature-backed insights to enhance assay reliability and translational impact.

• (5Z)-7-Oxozeaenol: Illuminating TAK1–SQSTM1 Crosstalk in Inf

  2026-06-29

  (5Z)-7-Oxozeaenol is a highly selective TAK1 inhibitor uniquely suited to dissecting the interplay between kinase signaling and cellular stress responses. This in-depth article explores how (5Z)-7-Oxozeaenol enables mechanistic insights into SQSTM1-mediated feedback loops, advancing inflammation research beyond standard protocols.

• Fluorescein TSA Kit: Precision Signal Amplification in Neuro

  2026-06-29

  Explore how the Fluorescein TSA Fluorescence System Kit empowers ultrasensitive, spatially precise detection in neurobiological research. Delve into advanced applications and novel assay strategies that set this cornerstone guide apart.

• H-Aggregated NIR-II Fluorophores Enable Enhanced Tumor PTT

  2026-06-28

  Yu et al. developed a lipid nanosystem that delivers H-aggregated NIR-II fluorophores and carboplatin to tumor cell membranes, achieving targeted photothermal and chemotherapeutic synergy. This work addresses longstanding inefficiencies in organic small-molecule fluorophore-based tumor therapies and enhances the stability and efficacy of photothermal conversion in vivo.

11415 records 2/761 page Previous Next 12345 下5页 Last page